Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | PTPRC | P08575 | 1/20 | 0.30 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
| ▸ | NQO1 | P15559 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19016875 | 0.77 | — | — | |
| SCHEMBL99907 | 0.73 | KMT2A (0.49) | MEN1KMT2ALMNA | |
| SCHEMBL9427607 | 0.73 | — | — | |
| SCHEMBL1021859 | 0.72 | — | — | |
| SCHEMBL6515435 | 0.69 | MEN1 (0.45) | MEN1KMT2ALMNA | |
| SCHEMBL7147326 | 0.68 | PGR (0.35) | ACHE | |
| SCHEMBL13933159 | 0.68 | GAA (0.32) | MEN1KMT2ALMNAPTPRCCDC25B | |
| SCHEMBL1128004 | 0.67 | ALDH1A1 (0.47) | MEN1KMT2ALMNA | |
| SCHEMBL13933157 | 0.67 | MEN1 (0.35) | MEN1KMT2ALMNAACHEPTGS2 | |
| SCHEMBL7383326 | 0.67 | ACHE (0.37) | MEN1KMT2ALMNAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| US-20240083900-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-03-14 | — | — | US | disclosed |
| EP-4244223-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | Biogen MA Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| CN-116783199-A | Pyrazolo [1,5-A ] pyrazine derivatives as BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2022-10-20 | — | — | US | disclosed |
| US-20220274967-A1 | BCAT MODULATION | ICAGEN, LLC | 2022-09-01 | — | — | US | disclosed |
| WO-2022104079-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2022104079-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| EP-3997080-A1 | BCAT MODULATION | Icagen, LLC (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-1965794-A2 | OCTAHYDROPYRANO[3,4-C]PYRROLE TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| EP-1124828-B1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LAB (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007075528-A2 | OCTAHYDROPYRANO[3,4-C]PYRROLE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-6642222-B2 | Useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions | ABBOTT LABORATORIES | 2003-11-04 | — | — | US | disclosed |
| US-20030055035-A1 | Pyrano piperidino and thiopyrano compounds and methods of use | ABBOTT LABORATORIES | 2003-03-20 | — | — | US | disclosed |
| EP-1278747-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | Abbott Laboratories (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001083484-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2001-11-08 | — | — | WO | disclosed |
| EP-1124828-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2001-08-22 | — | — | EP | disclosed |
| US-6191140-B1 | POTASSIUM CHANNEL MODULATORS; MUSCLE RELAXANTS; CONTROLLING CELL MEMBRANES | ABBOTT LABORATORIES | 2001-02-20 | — | — | US | disclosed |
| WO-2000024743-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055035-A1 | Pyrano piperidino and thiopyrano compounds and methods of use | KCNJ3, KCNJ6, KCNJ5 | MEN1 3482/4885KMT2A 3149/4885LMNA 2313/4885 |
| US-20220274967-A1 | BCAT MODULATION | BCAT2, BCAT1, ABAT | MEN1 2996/4885KMT2A 912/4885LMNA 3823/4885 |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | MEN1 2963/4885KMT2A 4104/4885LMNA 4878/4885 |
| US-20240083900-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BTK, SYK, LYN | MEN1 3706/4885KMT2A 1712/4885LMNA 4722/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | MEN1 2963/4885KMT2A 4104/4885LMNA 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.